Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Dec 05, 2022 3:34pm
249 Views
Post# 35151803

RE:45-60 days prior to strategy update

RE:45-60 days prior to strategy updateTH is guiding towards a trial restart by the end of the first quarter. Would I be shocked if it took longer than that? Not at all. There is always a chance there could be some back and forth between TH and the FDA that chews up some additional time.

They will need to get going on cost cutting right away so hopefully, they will update us quickly about that. I can understand them not sharing the specifics of the new trial protocol until the FDA has signed of on it, but it would be really bad form to leave us in the dark about all other aspects  of what is going on until the February Q4 conference call. 

Joemare wrote: I believe it's the minimum time before FDA comes back with a final decision regarding TH's proposal changes. I doubt we will get anything prior to that.   This PAUSE is a little worrisome as efficacy was the issue for the pause. Ex. If efficacy was an issue for 7/8 indications assess, the PR would have been much different and efficacy for the '8th' indication would have been detailed. I think they can't ascertain proof of concept yet + efficacy (partial/complete/stable response) is likely less than 20%.  

That sucks.  I can tell you that no one was blinede to the trial data. They knew back in the summer they had issues and response rate sucked.  I think heads should soon roll.


<< Previous
Bullboard Posts
Next >>